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Arterial tortuosity syndrome (ATS, MIM #208050) is a rare autosomal recessive connective tissue disorder 
characterized by tortuosity and elongation of the large and medium-sized arteries and a propensity 
towards aneurysm formation and vascular dissection. ATS is caused by mutations in SLC2A10 encoding the 
facilitative glucose transporter 10 (GLUT10), whose role in the ATS pathogenesis remains still controversial. 
We recently showed that GLUT10 deficiency causes the dysregulation of several genes/proteins involved in 
TGFβ signaling, extracellular matrix architecture and pathways that control oxidative stress response. 
GLUT10 should be located intracellularly; however, neither the exact localization, i.e., nuclear membrane, 
mitochondria, or endoplasmic reticulum (ER), nor the transported substances, i.e., glucose or 
dehydroascorbic acid (DAA), have been demonstrated.  
Here, we demonstrate that GLUT10 facilitates DAA uptake into the endomembranes and, in particular, into 
ER. GLUT10 produced by in vitro translation and incorporated into proteoliposomes efficiently transports 
DAA. Silencing of GLUT10 in hTERT immortalized human fibroblasts compromised DAA transport activity 
through the endomembranes. Similarly, in plasma membrane-permeabilized ATS fibroblasts a huge 
decrease in DAA transport was observed and the stable re-expression of GLUT10 restored the impaired 
DAA transport activity. Immunocytochemistry of human control fibroblasts showed a perinuclear 
abundance of GLUT10. Immunoblotting of subcellular fractions from human control fibroblasts revealed 
that GLUT10 was principally present in the microsomal fraction, containing ER-derived vesicles, as showed 
by the presence of the specific ER marker proteins GRP78 and GRP94, and by the almost complete absence 
of mitochondrial and cytoplasmic markers, VDAC1, cyclophilin D, and GAPDH, respectively. Transient 
expression of V5-tagged GLUT10 in ATS patients’ fibroblasts and co-localization experiments with the 
specific ER marker PDI definitely confirmed the ER localization of GLUT10.  
Overall, the present findings demonstrate that GLUT10 facilitates DAA uptake into the ER lumen and likely 
to the nucleoplasm through the nuclear envelope, which is a subdomain of the ER. Our findings support 
both “antioxidant-” and “enzyme cofactor-” models of a vitamin C-related pathology. Indeed, AA acts as an 
antioxidant/electron acceptor protecting against oxidative stress-induced cellular damage by scavenging 
free radicals also during the process of oxidative protein folding. Furthermore, AA is an essential cofactor 
for α-ketoglutarate-dependent dioxygenases, such as prolyl and lysyl hydroxylases inside the ER and for 
ten-eleven translocation demethylases and the Jumonji protein family present in the nucleus. Thus, 
shortage of AA in the lumenal compartments of the secretory pathway and in the nucleoplasm can depress 
the production of extracellular matrix proteins at both post-translational and epigenetic levels. 
